Biotech · Private company · Waltham, MA, US

Apellis Pharmaceuticals, Inc.

SEC CIK 0001492422

Track this companyFree. Adds Apellis Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials246 recruiting or active

Pipeline programs19From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline19

APL-2Phase 3 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
APL-2, PegcetacoplanPhase 3 · Geographic Atrophy Secondary to Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
APL2Phase 3 · FSGSClinicalTrials.gov · fetched Nov 12, 2026
PegcetacoplanPhase 3 · PNHClinicalTrials.gov · fetched Nov 12, 2026
PegcetacoplanPhase 3 · Paroxysmal Nocturnal HemoglobinuriaClinicalTrials.gov · fetched Nov 12, 2026
PegcetacoplanPhase 3 · C3GClinicalTrials.gov · fetched Nov 12, 2026
PEGCETACOPLAN (APL-2)Phase 3 · Geographic Atrophy Secondary to Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Sham ProcedurePhase 3 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
SolirisPhase 3 · Paroxysmal Nocturnal HemoglobinuriaClinicalTrials.gov · fetched Nov 12, 2026
APL-2Phase 2 · IgA NephropathyClinicalTrials.gov · fetched Nov 12, 2026
APL-2Phase 2 · Warm Autoimmune Hemolytic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
APL-3007, pegcetacoplan (APL-2)Phase 2 · Geographic Atrophy Secondary to Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
APL-9Phase 2 · COVIDClinicalTrials.gov · fetched Nov 12, 2026
PegcetacoplanPhase 2 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
PegcetacoplanPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
PegcetacoplanPhase 2 · Paroxysmal Nocturnal Hemoglobinuria (PNH)ClinicalTrials.gov · fetched Nov 12, 2026
Pegcetacoplan (APL-2)Phase 2 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
Vehicle ControlPhase 2 · COVIDClinicalTrials.gov · fetched Nov 12, 2026
PEGCETACOPLAN (APL-2)Phase 1 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials24

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisPHASE2_PHASE3 · RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07213960 · fetched Nov 12, 2026
Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).RECRUITING · started Jun 15, 2026ClinicalTrials.gov NCT07582042 · fetched Nov 12, 2026
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled SyringePHASE3 · COMPLETED · started Oct 24, 2025ClinicalTrials.gov NCT07214740 · fetched Nov 12, 2026
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioPHASE2 · RECRUITING · started Jun 23, 2025ClinicalTrials.gov NCT07215390 · fetched Nov 12, 2026
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationACTIVE_NOT_RECRUITING · started Sep 28, 2023ClinicalTrials.gov NCT06161584 · fetched Nov 12, 2026
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisPHASE3 · ACTIVE_NOT_RECRUITING · started May 29, 2023ClinicalTrials.gov NCT05809531 · fetched Nov 12, 2026
A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantationPHASE2 · COMPLETED · started Feb 1, 2022ClinicalTrials.gov NCT05148299 · fetched Nov 12, 2026
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisPHASE3 · COMPLETED · started Nov 12, 2021ClinicalTrials.gov NCT05067127 · fetched Nov 12, 2026
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGNPHASE2 · COMPLETED · started Sep 7, 2021ClinicalTrials.gov NCT04572854 · fetched Nov 12, 2026
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDPHASE3 · COMPLETED · started Mar 4, 2021ClinicalTrials.gov NCT04770545 · fetched Nov 12, 2026
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)PHASE2 · RECRUITING · started Feb 4, 2021ClinicalTrials.gov NCT04901936 · fetched Nov 12, 2026
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)PHASE2 · TERMINATED · started Sep 30, 2020ClinicalTrials.gov NCT04579666 · fetched Nov 12, 2026
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19PHASE1_PHASE2 · COMPLETED · started May 28, 2020ClinicalTrials.gov NCT04402060 · fetched Nov 12, 2026
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic AtrophyPHASE1 · COMPLETED · started Nov 5, 2018ClinicalTrials.gov NCT03777332 · fetched Nov 12, 2026
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationPHASE3 · COMPLETED · started Aug 31, 2018ClinicalTrials.gov NCT03525600 · fetched Nov 12, 2026
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationPHASE3 · COMPLETED · started Aug 31, 2018ClinicalTrials.gov NCT03525613 · fetched Nov 12, 2026
Pegcetacoplan Long Term Safety and Efficacy Extension StudyPHASE3 · COMPLETED · started Aug 27, 2018ClinicalTrials.gov NCT03531255 · fetched Nov 12, 2026
Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)PHASE3 · COMPLETED · started Jun 14, 2018ClinicalTrials.gov NCT03500549 · fetched Nov 12, 2026
Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesPHASE2 · COMPLETED · started Feb 26, 2018ClinicalTrials.gov NCT03453619 · fetched Nov 12, 2026
Pegcetacoplan (APL-2) in Neovascular AMDPHASE1_PHASE2 · TERMINATED · started Feb 14, 2018ClinicalTrials.gov NCT03465709 · fetched Nov 12, 2026
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)PHASE2 · COMPLETED · started Aug 31, 2017ClinicalTrials.gov NCT03226678 · fetched Nov 12, 2026
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic AtrophyPHASE2 · COMPLETED · started Sep 24, 2015ClinicalTrials.gov NCT02503332 · fetched Nov 12, 2026
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNHPHASE1 · COMPLETED · started Feb 23, 2015ClinicalTrials.gov NCT02264639 · fetched Nov 12, 2026
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMDPHASE1 · COMPLETED · started Jan 28, 2015ClinicalTrials.gov NCT02461771 · fetched Nov 12, 2026

SEC filings12

8-K · 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
10-K/A · 10-K/ASEC EDGAR · filed Apr 28, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Mar 2, 2026 · fetched Nov 12, 2026
10-K · 10-KSEC EDGAR · filed Feb 24, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Oct 30, 2025 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Jul 31, 2025 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 1, 2025 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 4, 2025 · fetched Nov 12, 2026